ReviewESMO gastrointestinal oncology2025
The prognostic role of Claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review.
Review in ESMO gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis.ESMO gastrointestinal oncology · 2026Review
- Article
- Human Epidermal Growth Factor Receptor 2-Positive, Claudin-18 Isoform 2-Positive, Mismatch Repair-Deficient Gastric Cancer Revealed by Immunohistochemical Analysis of Surgical Specimens: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Claudin 18.2 Expression and Outcomes of First-Line Chemoimmunotherapy in HER2-Negative Gastric or Gastroesophageal Junction Cancer: A Single-Center Retrospective Study.Current oncology (Toronto, Ont.) · 2026Article
- Diagnostic discordance and treatment-associated change of PD-L1 and CLDN18.2 in gastric cancer: a real-world analysis of paired biopsy-resection samples.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Claudin 18 isoform 2 (CLDN18.2) is a tight junction protein expressed in normal gastric tissue and retained in gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The phase III trials SPOTLIGHT and GLOW demonstrated improved survival following the addition of the CLDN18.2-targeted antibody zolbetuximab to chemotherapy. In this systematic literature review, we summarize existing evidence for the prognostic role of CLDN18.2 and association of CLDN18.2 with patient demographic and clinicopathological characteristics in patients with advanced G/GEJ adenocarcinoma. MEDLINE, Embase, clinical trials databases, and congress abstracts were searched for interventional and noninterventional studies that evaluated CLDN18.2 for patient/disease characteristics, survival, or expression of programmed death-ligand 1 as primary outcomes. Of 742 records identified, 18 publications (17 studies) were included. CLDN18.2 expression was not consistently associated with specific patient/disease characteristics in most studies; two studies reported an association of CLDN18.2 expression with Lauren classification but differed on its association with diffuse or intestinal histology. Most studies reported that CLDN18.2 expression was not a statistically significant prognostic factor; among those that reported CLDN18.2 as a prognostic factor, studies differed regarding the association of CLDN18.2 with worsened or improved prognosis. One study reported an association of CLDN18.2 expression with programmed death-ligand 1 expression. The use of different antibodies and definitions of CLDN18.2 positivity in patients with advanced G/GEJ adenocarcinoma poses a challenge for drawing definitive conclusions on the prognostic value of CLDN18.2 and association of CLDN18.2 with patient/disease characteristics. Additional research using a standardized approach to assess CLDN18.2 expression is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.